{"organizations": [], "uuid": "f35a2a1167caee638894c909a0d8e361e8423fab", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180508.html", "section_title": "Archive News &amp; Video for Tuesday, 08 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-miragen-announces-interim-data-fro/brief-miragen-announces-interim-data-from-phase-1-trial-of-cobomarsen-in-mycosis-fungoides-idUSASC0A0MU", "country": "US", "domain_rank": 408, "title": "BRIEF-Miragen Announces Interim Data From Phase 1 Trial Of Cobomarsen In Mycosis Fungoides", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.709, "site_type": "news", "published": "2018-05-09T06:46:00.000+03:00", "replies_count": 0, "uuid": "f35a2a1167caee638894c909a0d8e361e8423fab"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-miragen-announces-interim-data-fro/brief-miragen-announces-interim-data-from-phase-1-trial-of-cobomarsen-in-mycosis-fungoides-idUSASC0A0MU", "ord_in_thread": 0, "title": "BRIEF-Miragen Announces Interim Data From Phase 1 Trial Of Cobomarsen In Mycosis Fungoides", "locations": [], "entities": {"persons": [{"name": "cobomarsen", "sentiment": "none"}, {"name": "hase", "sentiment": "none"}], "locations": [{"name": "mycosis", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "therapeutics inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 8 (Reuters) - miRagen Therapeutics Inc:\n* MIRAGEN THERAPEUTICS ANNOUNCES NEW INTERIM DATA FROM PHASE 1 CLINICAL TRIAL OF COBOMARSEN IN MYCOSIS FUNGOIDES\n* MIRAGEN THERAPEUTICS INC - COBOMARSEN CONTINUED TO BE GENERALLY WELL TOLERATED AT ALL DOSE LEVELS EVALUATED\n* MIRAGEN THERAPEUTICS ANNOUNCES NEW INTERIM DATA FROM PHASE 1 CLINICAL TRIAL OF COBOMARSEN IN MYCOSIS FUNGOIDES Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-09T06:46:00.000+03:00", "crawled": "2018-05-09T12:33:19.020+03:00", "highlightTitle": ""}